Brief: IGC Says FDA Approves Initiation Of Co's Cannabinoid Trial On Alzheimer's Patients
Aug 11 (Reuters) - India Globalization Capital Inc IGC.A :
* FDA APPROVES INITIATION OF IGC’S CANNABINOID TRIAL ON
ALZHEIMER’S PATIENTS
* INDIA GLOBALIZATION CAPITAL INC - ANNOUNCES FDA REMOVAL OF
CLINICAL HOLD FOR MULTIPLE ASCENDING DOSE STUDY OF IGC-AD1
Source text for Eikon: ID:nBw29kLjLa
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment